[1]
Blegvad C, Skov L, Zachariae C. Ixekizumab for the treatment of psoriasis: an update on new data since first approval. Expert review of clinical immunology. 2019 Feb:15(2):111-121. doi: 10.1080/1744666X.2019.1559730. Epub 2018 Dec 27
[PubMed PMID: 30589394]
[2]
Pavelka K. Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. Vnitrni lekarstvi. 2021 Summer:67(4):195-200
[PubMed PMID: 34275303]
[3]
Atzeni F, Carriero A, Boccassini L, D'Angelo S. Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. ImmunoTargets and therapy. 2021:10():141-153. doi: 10.2147/ITT.S259126. Epub 2021 May 3
[PubMed PMID: 33977094]
[4]
Libon F, Lebas E, De Schaetzen V, Sabatiello M, De Schepper S, Nikkels AF. Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients. Expert review of clinical immunology. 2021 Sep:17(9):947-955. doi: 10.1080/1744666X.2021.1958675. Epub 2021 Jul 30
[PubMed PMID: 34328370]
[5]
Cather JC, Young CT, Young MS, Cather JC. Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis. Expert opinion on biological therapy. 2021 Aug:21(8):983-990. doi: 10.1080/14712598.2021.1931679. Epub 2021 Jun 9
[PubMed PMID: 34106794]
Level 3 (low-level) evidence
[7]
Harrison SR, Marzo-Ortega H. Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis. Expert review of clinical immunology. 2021 Oct:17(10):1059-1071. doi: 10.1080/1744666X.2021.1970534. Epub 2021 Aug 26
[PubMed PMID: 34407705]
[8]
Hawkes JE, See K, Burge R, Strakbein S, McKean-Matthews M, Saure D, Gooderham M, Leonardi C. Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis. Dermatology and therapy. 2021 Aug:11(4):1107-1118. doi: 10.1007/s13555-021-00548-2. Epub 2021 May 29
[PubMed PMID: 34050899]
[9]
Landewé RB, Gensler LS, Poddubnyy D, Rahman P, Hojnik M, Li X, Liu Leage S, Adams D, Carlier H, Van den Bosch F, COAST-Y study group. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Annals of the rheumatic diseases. 2021 Aug:80(8):1022-1030. doi: 10.1136/annrheumdis-2020-219717. Epub 2021 May 6
[PubMed PMID: 33958326]
Level 1 (high-level) evidence
[10]
Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, Okada M, Kerr L, Alves D, Park SY, Adams DH, Gallo G, Hufford MM, Hojnik M, Mease PJ, Kavanaugh A, SPIRIT-P3 Study Group. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study. Arthritis & rheumatology (Hoboken, N.J.). 2021 Sep:73(9):1663-1672. doi: 10.1002/art.41716. Epub 2021 Aug 6
[PubMed PMID: 33682378]
Level 1 (high-level) evidence
[11]
O'Brien-Gore C, Gray EH, Durham LE, Taams LS, Kirkham BW. Drivers of Inflammation in Psoriatic Arthritis: the Old and the New. Current rheumatology reports. 2021 Apr 28:23(6):40. doi: 10.1007/s11926-021-01005-x. Epub 2021 Apr 28
[PubMed PMID: 33909160]
[12]
Dong J, Goldenberg G. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors. Cutis. 2017 Feb:99(2):123-127
[PubMed PMID: 28319618]
[13]
Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis., Syed YY,, American journal of clinical dermatology, 2017 Feb
[PubMed PMID: 28138946]
[14]
Gooderham MJ, Elewski B, Augustin M, Iversen L, Torii H, Burge R, See K, Gallo G, Eastman WJ, McKean-Matthews M, Foley P. Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and -2 Studies. Journal of drugs in dermatology : JDD. 2021 Apr 1:20(4):394-401. doi: 10.36849/JDD.2021.5821. Epub
[PubMed PMID: 33852247]
Level 2 (mid-level) evidence
[15]
Blauvelt A, Lebwohl MG, Mabuchi T, Leung A, Garrelts A, Crane H, ElMaraghy H, Patel H, Ridenour T, See K, Gallo G, Paul C. Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial. Journal of the American Academy of Dermatology. 2021 Aug:85(2):360-368. doi: 10.1016/j.jaad.2020.11.022. Epub 2020 Nov 28
[PubMed PMID: 33253833]
Level 1 (high-level) evidence
[16]
Zhu N, Hou J. Exploring the mechanism of action Xianlingubao Prescription in the treatment of osteoporosis by network pharmacology. Computational biology and chemistry. 2020 Apr:85():107240. doi: 10.1016/j.compbiolchem.2020.107240. Epub 2020 Feb 26
[PubMed PMID: 32126522]
[17]
Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E. Ixekizumab for Patients with Plaque Psoriasis Affected by Multiple Sclerosis: Case report. Sultan Qaboos University medical journal. 2021 Aug:21(3):488-490. doi: 10.18295/squmj.4.2021.021. Epub 2021 Aug 29
[PubMed PMID: 34522419]
Level 3 (low-level) evidence
[18]
Berman J, Furer V, Berman M, Isakov O, Zisman D, Haddad A, Elkayam O. Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population. Biologics : targets & therapy. 2021:15():463-470. doi: 10.2147/BTT.S326792. Epub 2021 Nov 18
[PubMed PMID: 34819720]
[19]
Kim JH. Personalized dosing of ixekizumab for psoriasis. The British journal of dermatology. 2020 Jul:183(1):6. doi: 10.1111/bjd.18701. Epub 2019 Dec 2
[PubMed PMID: 31788787]
[20]
Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, Nott D, Liu-Leage S, Hartz S, Sapin C. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD open. 2020 Feb:6(1):. doi: 10.1136/rmdopen-2019-001117. Epub
[PubMed PMID: 32094304]
Level 1 (high-level) evidence
[21]
Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD, COAST-W Study Group. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis & rheumatology (Hoboken, N.J.). 2019 Apr:71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8
[PubMed PMID: 30343531]
Level 1 (high-level) evidence
[22]
Philipose J, Ahmed M, Idiculla PS, Mulrooney SM, Gumaste VV. Severe de novo Ulcerative Colitis following Ixekizumab Therapy. Case reports in gastroenterology. 2018 Sep-Dec:12(3):617-621. doi: 10.1159/000493922. Epub 2018 Oct 17
[PubMed PMID: 30483039]
Level 3 (low-level) evidence
[23]
Miller J, Puravath AP, Orbai AM. Ixekizumab for Psoriatic Arthritis: Safety, Efficacy, and Patient Selection. Journal of inflammation research. 2021:14():6975-6991. doi: 10.2147/JIR.S229752. Epub 2021 Dec 17
[PubMed PMID: 34949934]
[24]
Romozzi M, Bellavia S, Caldarola G, De Simone C, Luigetti M, Calabresi P, Di Filippo M, Masullo C, Lucchini M. Ixekizumab exposure associated with myelitis: A case report and a literature review. Journal of neuroimmunology. 2021 Dec 15:361():577726. doi: 10.1016/j.jneuroim.2021.577726. Epub 2021 Sep 29
[PubMed PMID: 34628135]
Level 3 (low-level) evidence
[25]
Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert opinion on biological therapy. 2018 Aug:18(8):897-903. doi: 10.1080/14712598.2018.1504016. Epub 2018 Jul 26
[PubMed PMID: 30032682]
Level 3 (low-level) evidence